Specific T-cell receptor beta-rearrangements of gluten-triggered CD8

Celiac disease Influenza A Refractory celiac disease Somatic recombination T-cell receptor

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
11 2023
Historique:
received: 13 07 2023
revised: 12 09 2023
accepted: 25 09 2023
medline: 6 11 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Celiac disease (CeD) is an autoimmune disorder affecting the small intestine with gluten as disease trigger. Infections including Influenza A, increase the CeD risk. While gluten-specific CD4

Identifiants

pubmed: 37769786
pii: S1521-6616(23)00558-2
doi: 10.1016/j.clim.2023.109795
pii:
doi:

Substances chimiques

Glutens 8002-80-0
Receptors, Antigen, T-Cell, alpha-beta 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109795

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest SH and VS are co-founders of HS Diagnomics. SS and AD are shareholders of HS Diagnomics, and VL holds the position of CS0 at HS Diagnomics. All other authors declare no competing interests.

Auteurs

V Seitz (V)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; HS Diagnomics GmbH, Berlin, Germany.

K Gennermann (K)

HS Diagnomics GmbH, Berlin, Germany.

S Elezkurtaj (S)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

D Groth (D)

Bioinformatics, Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany.

S Schaper (S)

HS Diagnomics GmbH, Berlin, Germany.

A Dröge (A)

HS Diagnomics GmbH, Berlin, Germany.

N Lachmann (N)

Centre for Tumor Medicine, Histocompatibility & Immunogenetics Laboratory, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

E Berg (E)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

D Lenze (D)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

A A Kühl (AA)

iPATH.Berlin - Core Unit of the Charité Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

C Husemann (C)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

K Kleo (K)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

D Horst (D)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

V Lennerz (V)

HS Diagnomics GmbH, Berlin, Germany.

S Hennig (S)

HS Diagnomics GmbH, Berlin, Germany.

M Hummel (M)

Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

M Schumann (M)

Medizinische Klinik m. S. Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: michael.schumann@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH